US widens scope of Rituxan to include life-threatening skin condition

PV is a rare, serious, potentially life-threatening condition characterised by progressive painful blistering of the skin and mucous membranes.

The condition accounts for up to 80 percent of cases of pemphigus, a group of autoimmune disorders affecting 30,000 to 40,000 people in the US.

Rituxan (rituximab) is the first biologic therapy approved by the FDA for the condition.

Clearance was based on data showing that 90 percent of PV patients treated with rituximab plus corticosteroids met the primary endpoint - complete remission at month 24 without the use of steroids for two or more months - compared to 28 percent those given corticosteroids alone.

The drug, which is sold as MabThera in Europe, is now approved to treat four autoimmune diseases, the others being rheumatoid arthritis, granulomatosis withpPolyangiitis (GPA; Wegener’s Granulomatosis) and microscopic polyangiitis (MPA).

-----------------------------------------------------------------------------------------------------------------------

Editor's Note:

To apply for becoming a contributor of en-CPhI.cn,

welcome to send your CV and sample works to us,

Email: Julia.Zhang@ubmsinoexpo.com.